Hydatid disease of the liver due to Echinococcus granulosus remains an important and challenging medical problem. It has a worldwide distribution and is endemic in sheep-rearing regions like the Mediterranean and Baltic, South America, Australia, New Zealand, Middle East and the Far East. Extensive population migration has led to an increasing incidence of the disease in non-endemic areas like England' and North America. 2 The liver hydatid cyst remains asymptomatic for years and then presents either due to local complications like pressure, rupture or infection or due to systemic hypersensitivity reactions.3 Rupture is usually into the biliary tract, peritoneal cavity or thoracic cavity and rarely into the vascular system, alimentary tract or urinary tract. 4 A high index of suspicion is essential to initiate a useful array of modem investigating facilities. Immunological testing has come a long way from the unpredictable Casoni's test and has a role not only in primary diagnosis, but also in screening of susceptible populations and post-surgical followup for recurrences.5 At present, for primary diagnosis, hydatid immunoelectrophoresis (HEP) and enzyme-linked immunosorbent assay (ELISA) are the tests of choice. For post-surgical follow-up for recurrent disease, HEP, and for large-scale screening of the susceptible population, ELISA are preferred. A plain X-ray of the abdomen may reveal curvilinear or ring-like calcification (pericyst) or several rings of calcification (daughter cysts) in up to 20-30% of the patients.6 Radionuclide scan reveals a space-occupying lesion, a nonspecific finding, in most of the cases.7 Ultrasound is a widely used and highly accurate test.8 Findings vary from a univesicular cyst without echogenic areas (Gharbi type I-difficult to differentiate from simple liver cysts) to a multiseptate cystic lesion with irregular echogenic areas within it or a complex heterogenous mass or a calcified mass (Type III, IV, V). Cases with cyst rupture into the biliary tree reveal echogenic material without acoustic shadowing in the bile duct,9 and rarely, cyst-biliary communication (pathognomonic of rupture'0°") may also be demonstrated. Computed tomographic (CT) scan has much the same findings, with enhancement of cyst septae on CT after intravenous injection of a cholangiographic contrast material being indicative of biliary communication.'2 Recently, the membrane detachment sign,'3 seen on CT scan after percutaneous aspiration of the cyst fluid, has been described as typical of hydatid cyst and is helpful in differentiating Gharbi type I hydatid cysts of the liver from simple liver cysts. The investigation of choice for confirmation and direct visualization ofcyst biliary communication is endoscopic retrograde cholangiopancreaticography (ERCP),"4-'6 which may reveal filiform linear filling defects (laminated membranes), rounded lucent filling defects (daughter cysts) or amorphous irregular material (both combined) in the bile duct,'7 apart from retrograde filling of the cyst itself by contrast from the bile duct. Duodenoscopy in these cases may reveal membranes protruding through the papilla.'8 Percutaneous transhepatic cholangiography also provides the same information'9 but is avoided by most people for fear of anaphylaxis and dissemination of the disease,6 though recent reports213 '20-22 prove this fear to be unfounded. In cases where cyst rupture is suspected intra-operatively, a peroperative cholangiogram provides the requisite information.5 Hepatic angiography is required only when a major hepatic resection is contemplated. Magnetic resonance imaging,23'24 which reveals curvilinear and ring-like low intensity structures within the cyst, is still under evaluation. A judicious combination of these investigative tools today allows us to make an accurate preoperative diagnosis of hydatid cyst as well as presence of complications, if any. This paves the way for a 'planned surgery' in these cases, thereby reducing the number of intra-operative surprises and postoperative complications.
Percutaneous aspiration of liver hydatid cysts for diagnostic and therapeutic purposes is an interesting new development and is being increasingly performed. for and under-running the cyst biliary connections at surgery, supplemented by an omentoplasty.30 Local recurrence is now being increasingly recognized to be due to the presence of exogenous cysts (outside the pericyst)38 which supposedly remain undetected and untreated during conservative procedures.32 However, these cysts, being reported in up to 23% of the patients undergoing total cystopericystectomy,38'39 can be picked up during conservative surgery also by the use of an intra-operative ultrasound.32 These observations negate the stated advantages of the radical procedures. Thus, without recommending any one of these as the 'standard' procedure for hydatid disease of the liver, we endorse the concept that the choice ofthe operative procedure is best left to the operating surgeon, who should take into consideration the site, size and number of the cyst(s), presence or absence of complications, condition of the patient and the surgical expertise available. No single procedure will suit all hydatid cysts.
Complicated liver hydatid cysts deserve separate mention here. Infected cysts should have external drainage33 with or without omentoplasty,5 after evacuation of its contents. Cysts with biliary rupture should have cholecystectomy and exploration of the common bile duct with meticulous clearance of all migrated hydatid material from it, preferably aided by an intra-operative choledochoscopy. 40 Instillation ofscolicidal substances directly into the duct should be avoided.4142 After exploration, the duct can be closed over a T-tube4344 or a choledocho-duodenostomy45 or transduodenal sphincteroplasty46 can be performed. Alternatively, duct clearance can be achieved by pre-operative endoscopic papillotomy, [47] [48] [49] The contribution of chemotherapy to the management of hydatid disease of the liver is growing. Mebendazole and flubendazole, used initially, have been discarded due to poor absorption and low serum and cyst fluid concentration. Albendazole, 5' another benzimidazole derivative and praziquintal,52 an isoquinoline derivative are currently most widely used. They achieve high serum and cyst fluid concentrations and are rapidly scolicidal. On the germinal membrane, however, albendazole is more effective.5 A recent WHO trial53 has recommended their use in inoperable cases (primary chemotherapy) and to prevent postoperative recurrences (adjuvant chemotherapy). For primary chemotherapy, albendazole 10 mg/kg/day is the drug of choice. In adjuvant setting either of these can be used. They may be given pre-operatively, to achieve 'sterilization' of the cysts (albendazole 10 mg/kg/ day for 4 weeks or praziquintal 50 mg/kg/day for 2 weeks) or postoperatively, in cases with cyst rupture before surgery or inadvertant spillage during surgery. Recently, both the drugs used together have been shown to be more effective in in vitro' and animal in vivo studies.5" Their combined use in human subjects is under evaluation. Primary chemotherapy as an alternative to surgery in operable cases is still controversial as no hard data are presently available.
